Aspire Biopharma Holdings, Inc. confirmed details of their 2024 Stock Incentive Plan, including a share limit of 4,890,000, approved by stockholders on February 4, 2025. The Board also approved new award agreements for stock options and restricted stock units on January 8, 2026.